Latest StemCells Inc. Stories
New findings demonstrate potential to treat a wide variety of disorders that affect myelin Physician-scientists at Oregon Health & Science University Doernbecher Children's Hospital have demonstrated for the first time that banked human neural stem cells — HuCNS-SCs, a proprietary product of StemCells Inc. — can survive and make functional myelin in mice with severe symptoms of myelin loss. Myelin is the critical fatty insulation, or sheath, surrounding new nerve fibers and is...
In a month, where the Pennsylvania Association for the Blind is creating awareness on Age-Related Macular Degeneration (AMD,) drug researcher StemCells Inc. (STEM) received authorization from the U.S. Food and Drug Administration (FDA) to start a clinical trial on the potential treatment for dry age-related macular degeneration. Mechanicsburg, Pennsylvania (PRWEB) February 17, 2012 In a month, where the Pennsylvania Association for the Blind is creating awareness on Age-Related Macular...
StemCells Inc. has filed for Swiss regulatory approval for clinical trials of its nerve stem cells in patients with spinal cord injuries, the company said.The stem cell research and development firm expects to enroll about a dozen patients whose injuries are as much as 12 months old. StemCells CEO Martin McGlynn said in a phone interview with Reuters that until now, the main focus has been on the "acute spinal cord injury phase." Although that is an important area that needs addressing, "the...
A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells. The research findings, published by Cell Press in the September 4th issue of the journal Cell Stem Cell, show that the transplanted cells provided a critical enzyme that was missing in the brains of the experimental mice and represent an important step toward what may be a successful therapeutic approach for a currently untreatable...
StemCells, Inc. (Nasdaq:STEM) announced today that results pertaining to the Company's research programs in retinal degeneration as well as spinal cord injury will be presented at the Society for Neuroscience Annual Meeting scheduled for November 15-19, 2008 in Washington, DC. The Society for Neuroscience is the world's largest organization devoted to advancing understanding of the brain and nervous system. Its annual meeting is one of the leading forums for neuroscientists from around the...
StemCells, Inc. (NASDAQ:STEM) announced today that it has entered into agreements to raise approximately $20 million in gross proceeds through the sale of approximately 13.8 million shares of its common stock to selected institutional investors at a price of $1.45 per share. The investors will also receive warrants to purchase approximately 10.3 million shares of common stock at an exercise price of $2.30 per share. The shares and warrants are being offered as a registered direct offering...
StemCells, Inc. (NASDAQ:STEM) reported today that its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells), when transplanted into a well-established animal model, can protect the retina from progressive degeneration. Retinal degeneration leads to loss of vision in diseases such as age-related macular degeneration and retinitis pigmentosa. This promising study was conducted by Dr. Raymond Lund, a researcher and professor at the Casey Eye Institute at Oregon Health &...
StemCells, Inc. (Nasdaq:STEM) announced today that it has been awarded a $305,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases to research and develop a potential cell-based therapeutic for liver disease arising from infection by the hepatitis C virus (HCV). Hepatitis C is a global health challenge, with approximately 170 million people affected worldwide and an estimated three million new infections each year. The virus targets liver cells and is a leading...
StemCells, Inc. (NASDAQ:STEM) today announced that Stewart Craig, Ph.D., an acknowledged expert in the development of cell-based therapeutics, will be joining the Company as Senior Vice President, Development and Operations, effective September 15, 2008. Dr. Craig will report to Martin McGlynn, the Company's President and Chief Executive Officer, and will be responsible for process design and engineering, GMP manufacturing operations, regulatory affairs, quality assurance, facilities and...
StemCells, Inc. (NASDAQ:STEM) today announced that it has accepted an invitation by the California Institute of Regenerative Medicine (CIRM) to present on Batten Disease at the upcoming meeting of CIRM's Independent Citizens Oversight Committee (ICOC). At the meeting, Ann Tsukamoto, Ph.D., the Company's Chief Operating Officer, and Stephen Huhn, M.D., F.A.C.S., F.A.A.P., Vice President and Head of the Company's CNS Program, will describe the Company's proprietary human neural stem cells and...
